{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T13:04:20Z","timestamp":1790255060785,"version":"4.1.0"},"reference-count":49,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012304","name":"School of Medicine, Johns Hopkins University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012304","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA269002"],"award-info":[{"award-number":["R01CA269002"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Oncology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.omton.2026.201284","type":"journal-article","created":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T23:44:30Z","timestamp":1782776670000},"page":"201284","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Oncolytic virus-mediated remodeling of tumor microenvironment enhances efficacy of an HPV16 E6\/E7 mRNA vaccine in an HPV-positive tumor"],"prefix":"10.1016","volume":"34","author":[{"given":"Kyle","family":"Johnson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanfu","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane JingTing","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nguyet","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2085-3997","authenticated-orcid":false,"given":"Shaun Xiaoliu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omton.2026.201284_bib1","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/ijc.30716","article-title":"Worldwide burden of cancer attributable to HPV by site, country and HPV type","volume":"141","author":"de Martel","year":"2017","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.omton.2026.201284_bib2","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.omton.2026.201284_bib3","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F","article-title":"Human papillomavirus is a necessary cause of invasive cervical cancer worldwide","volume":"189","author":"Walboomers","year":"1999","journal-title":"J. Pathol."},{"key":"10.1016\/j.omton.2026.201284_bib4","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/S1470-2045(10)70230-8","article-title":"Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study","volume":"11","author":"de Sanjose","year":"2010","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.omton.2026.201284_bib5","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/nrc2886","article-title":"Human papillomavirus oncoproteins: pathways to transformation","volume":"10","author":"Moody","year":"2010","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.omton.2026.201284_bib6","doi-asserted-by":"crossref","first-page":"11451","DOI":"10.1128\/JVI.78.21.11451-11460.2004","article-title":"Mechanisms of human papillomavirus-induced oncogenesis","volume":"78","author":"M\u00fcnger","year":"2004","journal-title":"J. Virol."},{"key":"10.1016\/j.omton.2026.201284_bib7","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s12929-016-0293-9","article-title":"Perspectives for therapeutic HPV vaccine development","volume":"23","author":"Yang","year":"2016","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.omton.2026.201284_bib8","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1016\/S0140-6736(96)90674-1","article-title":"A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer","volume":"347","author":"Borysiewicz","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.omton.2026.201284_bib9","doi-asserted-by":"crossref","first-page":"3975","DOI":"10.1016\/j.vaccine.2009.04.041","article-title":"The first clinical use of a live-attenuated Listeria monocytogenes vaccine: a Phase I safety study of Lm-LLO-E7 in patients with advanced carcinoma of the cervix","volume":"27","author":"Maciag","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.omton.2026.201284_bib10","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1056\/NEJMoa0810097","article-title":"Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia","volume":"361","author":"Kenter","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omton.2026.201284_bib11","first-page":"6451","article-title":"Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine","volume":"61","author":"Banchereau","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/j.omton.2026.201284_bib12","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1016\/S0140-6736(15)00239-1","article-title":"Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2\/3: a randomised, double-blind, placebo-controlled phase 2b trial","volume":"386","author":"Trimble","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.omton.2026.201284_bib13","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41541-023-00733-8","article-title":"mRNA-LNP vaccination-based immunotherapy augments CD8(+) T cell responses against HPV-positive oropharyngeal cancer","volume":"8","author":"Qiu","year":"2023","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.omton.2026.201284_bib14","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-012090","article-title":"mRNA-encoded mutant HPV16\/18 vaccines promote specific T-cell responses and synergize with anti-PD-1 checkpoint blockade in mediating therapeutic tumor regression in mice","volume":"13","author":"Zhang","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.omton.2026.201284_bib15","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1158\/1940-6207.CAPR-22-0413","article-title":"Safety Run-in of Intramuscular pNGVL4a-Sig\/E7(detox)\/HSP70 DNA and TA-CIN Protein Vaccination as Treatment for HPV16+ ASC-US, ASC-H, or LSIL\/CIN1","volume":"16","author":"Einstein","year":"2023","journal-title":"Cancer Prev. Res."},{"key":"10.1016\/j.omton.2026.201284_bib16","first-page":"1","article-title":"Progress in therapeutic HPV vaccines: observations from clinical trials","volume":"43","author":"Zhou","year":"2022","journal-title":"Eur. J. Gynaecol. Oncol."},{"key":"10.1016\/j.omton.2026.201284_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2024.115340","article-title":"A comprehensive comparison of DNA and RNA vaccines","volume":"210","author":"Wang","year":"2024","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.omton.2026.201284_bib18","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.29309","article-title":"mRNA-HPV vaccine encoding E6 and E7 improves therapeutic potential for HPV-mediated cancers via subcutaneous immunization","volume":"95","author":"Lee","year":"2023","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.omton.2026.201284_bib19","article-title":"HPV16 E6\/E7 -based mRNA vaccine is therapeutic in mice bearing aggressive HPV-positive lesions","volume":"14","author":"Zhou","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omton.2026.201284_bib20","doi-asserted-by":"crossref","DOI":"10.26508\/lsa.202302448","article-title":"Immunogenicity and effectiveness of an mRNA therapeutic vaccine for HPV-related malignancies","volume":"7","author":"Wang","year":"2024","journal-title":"Life Sci. Alliance"},{"key":"10.1016\/j.omton.2026.201284_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2025.125785","article-title":"Therapeutic mRNA vaccines targeting human papillomavirus type 16 E7 protein demonstrate significant antitumor efficacy in murine models of HPV-associated tumors","volume":"680","author":"Peng","year":"2025","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.omton.2026.201284_bib22","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/CJI.0000000000000156","article-title":"DNA Vaccine Encoding HPV16 Oncogenes E6 and E7 Induces Potent Cell-mediated and Humoral Immunity Which Protects in Tumor Challenge and Drives E7-expressing Skin Graft Rejection","volume":"40","author":"Chandra","year":"2017","journal-title":"J. Immunother."},{"key":"10.1016\/j.omton.2026.201284_bib23","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/s12033-016-9990-6","article-title":"Expression, Polyubiquitination, and Therapeutic Potential of Recombinant E6E7 from HPV16 Antigens Fused to Ubiquitin","volume":"59","author":"de Oliveira","year":"2017","journal-title":"Mol. Biotechnol."},{"key":"10.1016\/j.omton.2026.201284_bib24","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.ymthe.2006.02.007","article-title":"A mutant type 2 herpes simplex virus deleted for the protein kinase domain of the ICP10 gene is a potent oncolytic virus","volume":"13","author":"Fu","year":"2006","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omton.2026.201284_bib25","doi-asserted-by":"crossref","first-page":"902","DOI":"10.18632\/oncotarget.2817","article-title":"An HSV-2 based oncolytic virus can function as an attractant to guide migration of adoptively transferred T cells to tumor sites","volume":"6","author":"Fu","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.omton.2026.201284_bib26","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1007\/s00262-021-03084-2","article-title":"Comprehensive characterization of tumor immune landscape following oncolytic virotherapy by single-cell RNA sequencing","volume":"71","author":"Ravirala","year":"2022","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.omton.2026.201284_bib27","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.cell.2017.08.027","article-title":"Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy","volume":"170","author":"Ribas","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.omton.2026.201284_bib28","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.964442","article-title":"The role of PD-1\/PD-L1 and application of immune-checkpoint inhibitors in human cancers","volume":"13","author":"Tang","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omton.2026.201284_bib29","doi-asserted-by":"crossref","DOI":"10.1128\/MCB.00376-18","article-title":"Common and Differential Transcriptional Actions of Nuclear Receptors Liver X Receptors \u03b1 and \u03b2 in Macrophages","volume":"39","author":"Ram\u00f3n-V\u00e1zquez","year":"2019","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.omton.2026.201284_bib30","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-56038-1","article-title":"LXR-inverse agonism stimulates immune-mediated tumor destruction by enhancing CD8 T-cell activity in triple negative breast cancer","volume":"9","author":"Carpenter","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omton.2026.201284_bib31","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1007\/s12032-023-02027-4","article-title":"LXR inhibitor SR9243-loaded immunoliposomes modulate lipid metabolism and stemness in colorectal cancer cells","volume":"40","author":"Dianat-Moghadam","year":"2023","journal-title":"Med. Oncol."},{"key":"10.1016\/j.omton.2026.201284_bib32","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ccell.2015.05.007","article-title":"Broad Anti-tumor Activity of a Small Molecule that Selectively Targets the Warburg Effect and Lipogenesis","volume":"28","author":"Flaveny","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.omton.2026.201284_bib33","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.tim.2017.07.007","article-title":"The HPV E6\/E7 Oncogenes: Key Factors for Viral Carcinogenesis and Therapeutic Targets","volume":"26","author":"Hoppe-Seyler","year":"2018","journal-title":"Trends Microbiol."},{"key":"10.1016\/j.omton.2026.201284_bib34","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/S0140-6736(13)60022-7","article-title":"Human papillomavirus and cervical cancer","volume":"382","author":"Crosbie","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.omton.2026.201284_bib35","doi-asserted-by":"crossref","first-page":"3116","DOI":"10.3389\/fmicb.2019.03116","article-title":"Human Papillomavirus E6 and E7: The Cervical Cancer Hallmarks and Targets for Therapy","volume":"10","author":"Pal","year":"2019","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.omton.2026.201284_bib36","doi-asserted-by":"crossref","first-page":"600","DOI":"10.3390\/curroncol32110600","article-title":"Advances in Therapeutic Vaccines Against HPV: A Review of Human Clinical Trials","volume":"32","author":"Mart\u00edn","year":"2025","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.omton.2026.201284_bib37","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1146\/annurev.bi.61.070192.003553","article-title":"The ubiquitin system for protein degradation","volume":"61","author":"Hershko","year":"1992","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.omton.2026.201284_bib38","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1146\/annurev-biochem-051710-093308","article-title":"The N-End Rule Pathway","volume":"81","author":"Tasaki","year":"2012","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.omton.2026.201284_bib39","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1038\/nri1250","article-title":"Making sense of mass destruction: quantitating MHC class I antigen presentation","volume":"3","author":"Yewdell","year":"2003","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.omton.2026.201284_bib40","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/S0264-410X(01)00406-6","article-title":"Polynucleotide viral vaccines: codon optimisation and ubiquitin conjugation enhances prophylactic and therapeutic efficacy","volume":"20","author":"Liu","year":"2001","journal-title":"Vaccine"},{"key":"10.1016\/j.omton.2026.201284_bib41","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.03224-20","article-title":"Development of DNA Vaccine Targeting E6 and E7 Proteins of Human Papillomavirus 16 (HPV16) and HPV18 for Immunotherapy in Combination with Recombinant Vaccinia Boost and PD-1 Antibody","volume":"12","author":"Peng","year":"2021","journal-title":"mBio"},{"key":"10.1016\/j.omton.2026.201284_bib42","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1001\/jamaoncol.2018.4051","article-title":"Combining Immune Checkpoint Blockade and Tumor-Specific Vaccine for Patients With Incurable Human Papillomavirus 16\u2013Related Cancer: A Phase 2 Clinical Trial","volume":"5","author":"Massarelli","year":"2019","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.omton.2026.201284_bib43","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004232","article-title":"ISA101 and nivolumab for HPV-16+ cancer: updated clinical efficacy and immune correlates of response","volume":"10","author":"Sousa","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.omton.2026.201284_bib44","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1007\/s00262-020-02754-x","article-title":"PD-1 blockade synergizes with intratumoral vaccination of a therapeutic HPV protein vaccine and elicits regression of tumor in a preclinical model","volume":"70","author":"Peng","year":"2021","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.omton.2026.201284_bib45","doi-asserted-by":"crossref","DOI":"10.3390\/ijms262412121","article-title":"HPV-Driven Immune Evasion in Cervical Cancer: Transcriptomic Identification of Downregulated Hub Genes and Suppressed Leukocyte Migration Pathways","volume":"26","author":"Ismael Ameen","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.omton.2026.201284_bib46","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1158\/2159-8290.CD-20-1760","article-title":"Tumor Immunity and Immunotherapy for HPV-Related Cancers","volume":"11","author":"Shamseddine","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.omton.2026.201284_bib47","doi-asserted-by":"crossref","first-page":"682","DOI":"10.3389\/fonc.2019.00682","article-title":"Papillomavirus Immune Evasion Strategies Target the Infected Cell and the Local Immune System","volume":"9","author":"Zhou","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.omton.2026.201284_bib48","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.omtn.2019.02.018","article-title":"A Facile Method for the Removal of dsRNA Contaminant from In Vitro-Transcribed mRNA","volume":"15","author":"Baiersd\u00f6rfer","year":"2019","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omton.2026.201284_bib49","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0011867","article-title":"A simple and sensitive method for measuring tumor-specific T cell cytotoxicity","volume":"5","author":"Fu","year":"2010","journal-title":"PLoS One"}],"container-title":["Molecular Therapy Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950329926001608?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950329926001608?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T12:32:40Z","timestamp":1790253160000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950329926001608"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":49,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S2950329926001608"],"URL":"https:\/\/doi.org\/10.1016\/j.omton.2026.201284","relation":{},"ISSN":["2950-3299"],"issn-type":[{"value":"2950-3299","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oncolytic virus-mediated remodeling of tumor microenvironment enhances efficacy of an HPV16 E6\/E7 mRNA vaccine in an HPV-positive tumor","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omton.2026.201284","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"201284"}}